Principal Scientist, Translational Computational Biology

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits.

This is work that transforms the lives of patients, and the careers of those who do it.

When you join BMS, you are joining a high-achieving team united by a common mission.

The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development and across all therapeutic areas  do this in close partnership with scientific and clinical experts in the field, both inside and outside the company.

We perform innovative science to empower key data-driven decisions across a rich pipeline of next-generation medicines. In doing so, our work transforms the lives of patients, as well as our own lives and careers.

Here, you’ll get the chance to grow and thrive through opportunities that are uncommon in scale and scope. You’ll pursue innovative ideas while advancing professionally alongside some of the brightest minds in biopharma.

The Oncology Translational IPS team is seeking a Principal Scientist, Translational Computational Biology, to serve as the computational partner to our oncology drug development programs across discovery, translational research, and early clinical development. You will translate patient-derived molecular, spatial, and clinical data into biomarker hypotheses, patient stratification strategies, indication prioritization, pharmacodynamic readouts, and decision-grade recommendations.

The majority of the role is embedded with oncology drug development programs and clinical development teams. The remainder builds computational capability for the broader portfolio: spatial biology, AI-enabled translational science, and reusable analytical methods. The exact emphasis of that capability work will evolve with portfolio priorities and emerging technologies.

This role is for someone who understands drug development, not only data analysis. We are looking for a scientist with a working understanding of the path from target validation and candidate selection through IND-enabling work and early clinical studies (including dose escalation and expansion), and of the strategic role biomarkers play at each stage, who can carry an interpretation into the forum where the decision is actually made.

Spatial transcriptomics and spatial proteomics / multiplex immunofluorescence. Dedicated analytical ownership across multiple concurrent oncology programs, on the platforms the team runs today:
Xenium, Visium, and Visium HD for spatial transcriptomics, and platforms such as COMET or Pheno Cycler for spatial proteomics / multiplex immunofluorescence. Backed by a pan-cancer spatial atlas license, an H&E-to-mIF platform partnership, and cloud compute alongside a translational informatics team that builds its own methods. These platforms are already funded and running; this role exists to realize their scientific value.

Clinical and multi-modal patient-derived datasets from BMS’s industry-leading early-stage…